SCOTUS hears Amgen v Sandoz biosimilar dispute

27-04-2017

SCOTUS hears Amgen v Sandoz biosimilar dispute

AVNphotolab / iStockphoto.com

The US Supreme Court heard oral arguments from Amgen and Sandoz yesterday in the ongoing battle over a biosimilar version of Amgen’s Neupogen (filgrastim).


SCOTUS, Amgen, Sandoz, BPCIA, patent, biosimilar, biologics, FDA, Federal Circuit

LSIPR